Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CD55 / Decay Accelerating Factor (DAF) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone 143-30 ]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC-F, IF, FC |
|---|---|
| Primary Accession | P08174 |
| Other Accession | 1604, 126517 |
| Reactivity | Human |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | Mouse / IgG1, kappa |
| Clone Names | 143-30 |
| Calculated MW | 70kDa |
| Gene ID | 1604 |
|---|---|
| Other Names | Complement decay-accelerating factor, CD55, CD55, CR, DAF |
| Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
| Precautions | CD55 / Decay Accelerating Factor (DAF) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | CD55 |
|---|---|
| Synonyms | CR, DAF |
| Function | This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade (PubMed:7525274). Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage (PubMed:28657829). |
| Cellular Location | [Isoform 1]: Cell membrane; Single-pass type I membrane protein [Isoform 3]: Secreted [Isoform 5]: Secreted [Isoform 7]: Cell membrane; Lipid-anchor, GPI-anchor |
| Tissue Location | Expressed on the plasma membranes of all cell types that are in intimate contact with plasma complement proteins. It is also found on the surfaces of epithelial cells lining extracellular compartments, and variants of the molecule are present in body fluids and in extracellular matrix |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Recognizes a single chain glycoprotein of 70kDa, identified as CD55 (also known as decay accelerating factor, DAF). CD55/DAF is widely expressed on cells throughout the body including leukocytes, erythrocytes, epithelium, endothelium, and fibroblasts. It is a Glycosyl phosphatidylinositol anchored (GPI-anchored) member of the membrane bound complement regulatory proteins that inhibit autologous complement cascade activation. It prevents the amplification steps of the complement cascade by interfering with the assembly of the C3-convertases, C4b2a and C3bBb, and the C5-convertase, C4b2a3b and C3bBb3b. CD55 also serves as receptor for CD97 and for echovirus and Coxsackie B virus. The MAb 143-30 can be used as marker for paroxysmal nocturnal hemoglobinuria (PNH).
References
Schlossman S et al. (eds) Leukocyte Typing V. Oxford University Press, Oxford, 1995. Kishimoto T. et al., eds. Leukocyte Typing VI, Garland Publishing, Inc, New York and London, 1997.Koretz, K. et al., Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. British J. Cancer 66: 810-814, (1992). | Knapp, W. et al., Leucocyte typing IV, pp 541, 694-697, 1088. Oxford Univ
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
